SLU-PP-332
Janoshik
Batch SLU-CA-26A-01
SLU-PP-332 Capsules
PPARδ Agonist Research Compound
SLU-PP-332 Capsules are a solid-dose research format used in laboratory studies to investigate compounds involved in metabolic and mitochondrial signaling pathways. Research often examines their influence on energy utilization processes, cellular regulation mechanisms, and systemic metabolic responses in controlled experimental models.
🔬 This product is coming soon — ordering is not yet available.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
SLU-PP-332 is a small-molecule research compound studied as a selective peroxisome proliferator-activated receptor delta (PPARδ) agonist. It is developed for controlled laboratory investigation involving nuclear receptor signaling systems.
In scientific literature, SLU-PP-332 is examined in experimental models evaluating PPARδ-associated transcriptional pathways, metabolic regulatory frameworks, and receptor-mediated gene expression systems under in vitro and preclinical research conditions.
Third-party tested for purity, identity, quantity.
SLU-PP-332 is evaluated in research focused on PPARδ receptor activation and nuclear receptor–mediated transcriptional regulation. Experimental studies examine receptor-binding dynamics and downstream gene expression signaling systems within controlled laboratory environments.
Research frameworks explore its interaction with metabolic regulatory pathways and transcriptional signaling models under structured experimental conditions.
Research into peroxisome proliferator-activated receptors (PPARs) led to the development of selective receptor agonists for experimental evaluation. Compounds targeting PPARδ have been studied for their role in transcriptional regulation and metabolic signaling systems.
SLU-PP-332 emerged within this research context as a selective agonist evaluated in controlled laboratory models examining nuclear receptor pathway interaction.
Laboratory investigations into SLU-PP-332 have focused on PPARδ activation models and nuclear receptor–mediated gene expression systems. Research frameworks evaluate receptor-binding interaction, transcriptional pathway regulation, and metabolic signaling mechanisms under controlled in vitro and preclinical conditions.
0 of the 4 areas below are addressed directly by a paper cited on this page.
PPARδ receptor activation models
No paper cited on this page reports on ppar, receptor or activation. This heading marks where SLU-PP-332 Capsules is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Nuclear receptor transcriptional regulation studies
No paper cited on this page reports on nuclear, receptor or transcriptional. This heading marks where SLU-PP-332 Capsules is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Metabolic signaling pathway research
No paper cited on this page reports on metabolic. This heading marks where SLU-PP-332 Capsules is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Gene expression regulatory framework investigations
No paper cited on this page reports on gene or expression. This heading marks where SLU-PP-332 Capsules is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 1 primary paper published in 2018 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
SLU-PP-332 Capsules is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for SLU-PP-332 Capsules, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
SLU-PP-332 Capsules is also referred to as SLU-PP-332, the exercise mimetic.
SLU-PP-332 Capsules is commonly described online in connection with weight loss, appetite suppression and fat reduction. In the research literature the same compound is filed under PPARδ receptor activation models, nuclear receptor transcriptional regulation studies and metabolic signaling pathway research.
The 1 paper cited on this page, published in 2018 describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Presented alongside compounds with decades of published research, as though the evidence base is comparable.
It is not. SLU-PP-332 Capsules rests on 1 cited paper (in 2018). A record that thin cannot support conclusions about mechanism, effect or safety, and the honest reading is that this compound has been studied very little rather than studied and validated.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for SLU-PP-332 Capsules is per lot, not per product. The current lot SLU-CA-26A-01 returned 666.72 mg measured, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
The lot code printed on the bottle matches the code on the certificate for SLU-PP-332 Capsules. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy SLU-PP-332 Capsules in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Storage
- Cool, dry, away from direct light
- Humidity
- Keep sealed; capsule shells are hygroscopic
- Reconstitution
- Not applicable — supplied pre-measured
- Format
- Oral capsule
SLU-PP-332 Capsules is supplied in capsule form, which removes the reconstitution step entirely: there is no vehicle to add, no reconstitution volume to record and no post-reconstitution stability window to track. What that leaves a laboratory to control is storage — capsule shells draw moisture from the air, so the container should be kept sealed and dry rather than decanted into an open vessel.
Because the material is already at its labelled quantity per capsule, batch verification carries more weight in this format than it does for powder: there is no point at which the researcher independently confirms mass by weighing. The measured content published for each lot is the figure that answers that question.
- 1 × sealed capsule bottle (500 mcg / Single Bottle - Pack of 60), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Laboratory consumables of any kind
- Dosing, administration or protocol guidance of any kind
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each capsule contains the labeled quantity of SLU-PP-332. Independent third-party testing verifies purity, identity, and batch specifications prior to release.
The product is supplied in capsule form for laboratory research purposes. No additional materials are included.
Duration depends entirely on research protocol, storage conditions, and laboratory application.
Design, synthesis, and evaluation of simple phenol amides as ERRγ agonists.
PubMedRelated
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99